Некоторое содержание этого приложения в настоящий момент недоступно.
Если эта ситуация сохраняется, свяжитесь с нами по адресуОтзывы и контакты
1. (WO2019067021) COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH ABNORMAL STEROIDOGENESIS
Примечание: Текст, основанный на автоматизированных процессах оптического распознавания знаков. Для юридических целей просьба использовать вариант в формате PDF

WHAT IS CLAIMED IS:

1. A compound of Formula la:


la

or a pharmaceutically acceptable salt thereof, wherein:

each R1 is an independently selected C1-6 alkoxy;

or, alternatively, two adjacent R1 groups, together with the carbon atoms to which they are attached, form an aryl ring having 6 to 10 ring carbon atoms;

R2 is Ci-4 alkyl;

R3 is Ci-4 alkyl; and

p is 2 or 3.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein p is 2.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each R1 is methoxy.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each R1 is methoxy, and p is 2.

5. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein two adjacent R1 groups, together with the carbon atoms to which they are attached, form an aryl ring having 6 to 10 ring carbon atoms.

6. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein two adjacent R1 groups, together with the carbon atoms to which they are attached, form an aryl ring having 6 ring carbon atoms.

7. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R2 is methyl.

8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R3 is ethyl.

9. The compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R2 is methyl and R3 is ethyl.

10. The compound of claim 1, wherein the compound of Formula I is a compound of Formula II:


II

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I is a com ound of Formula III:


III

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I is a compound of Formula TV:


IV

or a pharmaceutically acceptable salt thereof, wherein ring A is an aryl ring having 6 to 10 ring carbon atoms.

13. The compound of claim 1, wherein the compound of Formula I is a compound of Formula V:


V

or a pharmaceutically acceptable salt thereof, wherein ring A is an aryl ring having 6 to 10 ring carbon atoms.

The compound of claim 1, wherein the compound of Formula I is a compound of


VI

or a pharmaceutically acceptable salt thereof, wherein ring A is an aryl ring having 6 to 10 ring carbon atoms.

15. The compound of claim 1, wherein the compound of Formula I is selected from the group consisting of:


or a pharmaceutically acceptable salt thereof.

16. The compound of claim 1, wherein the compound of Formula I is selected from the group consisting of:


or a pharmaceutically acceptable salt thereof.

The compound of claim 1 wherein the compound of Formula I


or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition, comprising a compound of any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

A method of inhibiting steroidogenesis in a cell or tissue, comprising contacting or tissue with a compound of Formula I:


I

or a pharmaceutically acceptable salt thereof, wherein:

each R1 is independently selected from the group consisting of halo and C1 -6 alkoxy;

or, alternatively, two adjacent R1 groups, together with the carbon atoms to which they are attached, form an aryl ring having 6 to 10 ring carbon atoms;

R2 is Ci-4 alkyl;

R3 is C alkyl; and

p is 1, 2, or 3.

20. A method of inhibiting steroidogenesis in a subject, comprising administering to the subject a therapeutically effective amount of a com ound of Formula I:


I

or a pharmaceutically acceptable salt thereof, wherein:

each R1 is independently selected from the group consisting of halo and Ci -6 alkoxy;

or, alternatively, two adjacent R1 groups, together with the carbon atoms to which they are attached, form an aryl ring having 6 to 10 ring carbon atoms;

R2 is Ci-4 alkyl;

R3 is Ci-4 alkyl; and

p is 1, 2, or 3.

21. The method of claim 19 or 20, wherein the method of inhibiting steroidogenesis comprises inhibiting adrenocortical steroid synthesis.

22. A method of inhibiting 11 β-hydroxylase activity in a cell or tissue, comprising contacting the cell or tissue with a compound of Formula I:


I

or a pharmaceutically acceptable salt thereof, wherein:

each R1 is independently selected from the group consisting of halo and Ci -6 alkoxy;

or, alternatively, two adjacent R1 groups, together with the carbon atoms to which they are attached, form an aryl ring having 6 to 10 ring carbon atoms;

R2 is Ci-4 alkyl;

R3 is C alkyl; and

p is 1, 2, or 3.

23. A method of inhibiting 11 β-hydroxylase activity in a subject, comprising administering to the subject a therapeutically effective amount of a compound of Formula I:


I

or a pharmaceutically acceptable salt thereof, wherein:

each R is independently selected from the group consisting of halo and C1 -6 alkoxy;

or, alternatively, two adjacent R1 groups, together with the carbon atoms to which they are attached, form an aryl ring having 6 to 10 ring carbon atoms;

R2 is Ci-4 alkyl;

R3 is C alkyl; and

p is 1, 2, or 3.

24. A method of treating a disease associated with abnormal steroidogenesis in a subject, comprising administering to the subject a compound of Formula I:


I

or a pharmaceutically acceptable salt thereof, wherein:

each R1 is independently selected from the group consisting of halo and Ci-6 alkoxy;

or, alternatively, two adjacent R1 groups, together with the carbon atoms to which they are attached, form an aryl ring having 6 to 10 ring carbon atoms;

R2 is Ci-4 alkyl;

R3 is Ci-4 alkyl; and

p is 1, 2, or 3.

25. The method of claim 24, wherein the disease is selected from the group consisting of Cushing's syndrome, hypercortisolemia, hypertension, diabetes, immunosuppression, water retention, depression, poor wound healing, fatigue, or any combination thereof.

26. The method of claim 24 or 25, wherein the disease is Cushing's syndrome.

27. The method of any one of claims 20, 21, and 23 to 26, wherein the therapeutically effective amount is an amount such that the subject does not exhibit a loss of righting reflex.

28. The method of any one of claims 20, 21, and 23 to 26, wherein the therapeutically effective amount is an amount such that the subject does not exhibit loss of

consciousness.

29. The method of any one of claims 20, 21, and 23 to 26, wherein the therapeutically effective amount is an amount such that the subject does not exhibit loss of consciousness associated with enhanced receptor function of the GABAA receptor.

30. The method of any one of claims 19 to 29, wherein the compound of Formula I is a compound of Formula la:


la

or a pharmaceutically acceptable salt thereof, wherein:

each R1 is an independently selected C1-6 alkoxy;

or, alternatively, two adjacent R1 groups, together with the carbon atoms to which they are attached, form an aryl ring having 6 to 10 ring carbon atoms;

R2 is Ci-4 alkyl;

R3 is C alkyl; and

p is 2 or 3.

31. The method of any one of claims 19 to 29, wherein the compound is selected from the group consisting of:


or a pharmaceutically acceptable salt thereof.

32. The method of any one of claims 19 to 29, wherein the compound is selected from the group consisting of:


or a pharmaceutically acceptable salt thereof.

33. The method of any one of claims 19 to 30, wherein the compound is selected from the group consisting of:

34. The method of any one of claims 19 to 30, wherein the compound is selected from the group consisting of:


or a pharmaceutically acceptable salt thereof.

The method of any one of claims 19 to 30 wherein the compound


or a pharmaceutically acceptable salt thereof.